272 related articles for article (PubMed ID: 30952114)
1. First clinical experience with DRD2/3 antagonist ONC201 in H3 K27M-mutant pediatric diffuse intrinsic pontine glioma: a case report.
Hall MD; Odia Y; Allen JE; Tarapore R; Khatib Z; Niazi TN; Daghistani D; Schalop L; Chi AS; Oster W; Mehta MP
J Neurosurg Pediatr; 2019 Apr; 23(6):719-725. PubMed ID: 30952114
[TBL] [Abstract][Full Text] [Related]
2. Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201.
Chi AS; Tarapore RS; Hall MD; Shonka N; Gardner S; Umemura Y; Sumrall A; Khatib Z; Mueller S; Kline C; Zaky W; Khatua S; Weathers SP; Odia Y; Niazi TN; Daghistani D; Cherrick I; Korones D; Karajannis MA; Kong XT; Minturn J; Waanders A; Arillaga-Romany I; Batchelor T; Wen PY; Merdinger K; Schalop L; Stogniew M; Allen JE; Oster W; Mehta MP
J Neurooncol; 2019 Oct; 145(1):97-105. PubMed ID: 31456142
[TBL] [Abstract][Full Text] [Related]
3. Selective DRD2 antagonist and ClpP agonist ONC201 in a recurrent non-midline H3 K27M-mutant glioma cohort.
Odia Y; Hall MD; Cloughesy TF; Wen PY; Arrillaga-Romany I; Daghistani D; Mehta MP; Tarapore RS; Ramage SC; Allen JE
Neuro Oncol; 2024 May; 26(Supplement_2):S165-S172. PubMed ID: 38386699
[TBL] [Abstract][Full Text] [Related]
4. Phase I dose escalation and expansion trial of single agent ONC201 in pediatric diffuse midline gliomas following radiotherapy.
Gardner SL; Tarapore RS; Allen J; McGovern SL; Zaky W; Odia Y; Daghistani D; Diaz Z; Hall MD; Khatib Z; Koschmann C; Cantor E; Kurokawa R; MacDonald TJ; Aguilera D; Vitanza NA; Mueller S; Kline C; Lu G; Allen JE; Khatua S
Neurooncol Adv; 2022; 4(1):vdac143. PubMed ID: 36382108
[TBL] [Abstract][Full Text] [Related]
5. Clinical, imaging, and molecular analysis of pediatric pontine tumors lacking characteristic imaging features of DIPG.
Chiang J; Diaz AK; Makepeace L; Li X; Han Y; Li Y; Klimo P; Boop FA; Baker SJ; Gajjar A; Merchant TE; Ellison DW; Broniscer A; Patay Z; Tinkle CL
Acta Neuropathol Commun; 2020 Apr; 8(1):57. PubMed ID: 32326973
[TBL] [Abstract][Full Text] [Related]
6. Diffuse Intrinsic Pontine Glioma: From Diagnosis to Next-Generation Clinical Trials.
Vitanza NA; Monje M
Curr Treat Options Neurol; 2019 Jul; 21(8):37. PubMed ID: 31290035
[TBL] [Abstract][Full Text] [Related]
7. Histone H3F3A and HIST1H3B K27M mutations define two subgroups of diffuse intrinsic pontine gliomas with different prognosis and phenotypes.
Castel D; Philippe C; Calmon R; Le Dret L; Truffaux N; Boddaert N; Pagès M; Taylor KR; Saulnier P; Lacroix L; Mackay A; Jones C; Sainte-Rose C; Blauwblomme T; Andreiuolo F; Puget S; Grill J; Varlet P; Debily MA
Acta Neuropathol; 2015 Dec; 130(6):815-27. PubMed ID: 26399631
[TBL] [Abstract][Full Text] [Related]
8. ONC201 (Dordaviprone) in Recurrent H3 K27M-Mutant Diffuse Midline Glioma.
Arrillaga-Romany I; Gardner SL; Odia Y; Aguilera D; Allen JE; Batchelor T; Butowski N; Chen C; Cloughesy T; Cluster A; de Groot J; Dixit KS; Graber JJ; Haggiagi AM; Harrison RA; Kheradpour A; Kilburn LB; Kurz SC; Lu G; MacDonald TJ; Mehta M; Melemed AS; Nghiemphu PL; Ramage SC; Shonka N; Sumrall A; Tarapore RS; Taylor L; Umemura Y; Wen PY
J Clin Oncol; 2024 May; 42(13):1542-1552. PubMed ID: 38335473
[TBL] [Abstract][Full Text] [Related]
9. H3 K27M-altered glioma and diffuse intrinsic pontine glioma: Semi-systematic review of treatment landscape and future directions.
van den Bent M; Saratsis AM; Geurts M; Franceschi E
Neuro Oncol; 2024 May; 26(Supplement_2):S110-S124. PubMed ID: 38102230
[TBL] [Abstract][Full Text] [Related]
10. K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas.
Khuong-Quang DA; Buczkowicz P; Rakopoulos P; Liu XY; Fontebasso AM; Bouffet E; Bartels U; Albrecht S; Schwartzentruber J; Letourneau L; Bourgey M; Bourque G; Montpetit A; Bourret G; Lepage P; Fleming A; Lichter P; Kool M; von Deimling A; Sturm D; Korshunov A; Faury D; Jones DT; Majewski J; Pfister SM; Jabado N; Hawkins C
Acta Neuropathol; 2012 Sep; 124(3):439-47. PubMed ID: 22661320
[TBL] [Abstract][Full Text] [Related]
11. Tectal Low-Grade Glioma with H3 K27M Mutation.
Sumi K; Shijo K; Igarashi T; Yamamuro S; Sasano M; Oshima H; Ishige T; Honma T; Yagasaki H; Yoshino A
World Neurosurg; 2020 Sep; 141():91-100. PubMed ID: 32505657
[TBL] [Abstract][Full Text] [Related]
12. Biological activity of weekly ONC201 in adult recurrent glioblastoma patients.
Arrillaga-Romany I; Odia Y; Prabhu VV; Tarapore RS; Merdinger K; Stogniew M; Oster W; Allen JE; Mehta M; Batchelor TT; Wen PY
Neuro Oncol; 2020 Jan; 22(1):94-102. PubMed ID: 31702782
[TBL] [Abstract][Full Text] [Related]
13. Pediatric Diffuse Midline Gliomas H3 K27M-Mutant and Non-Histone Mutant Midline High-Grade Gliomas in Neurofibromatosis Type 1 in Comparison With Non-Syndromic Children: A Single-Center Pilot Study.
Garibotto F; Madia F; Milanaccio C; Verrico A; Piccardo A; Tortora D; Piatelli G; Diana MC; Capra V; Garrè ML; Rossi A; Morana G
Front Oncol; 2020; 10():795. PubMed ID: 32582540
[No Abstract] [Full Text] [Related]
14. H3.3 K27M depletion increases differentiation and extends latency of diffuse intrinsic pontine glioma growth in vivo.
Silveira AB; Kasper LH; Fan Y; Jin H; Wu G; Shaw TI; Zhu X; Larson JD; Easton J; Shao Y; Yergeau DA; Rosencrance C; Boggs K; Rusch MC; Ding L; Zhang J; Finkelstein D; Noyes RM; Russell BL; Xu B; Broniscer A; Wetmore C; Pounds SB; Ellison DW; Zhang J; Baker SJ
Acta Neuropathol; 2019 Apr; 137(4):637-655. PubMed ID: 30770999
[TBL] [Abstract][Full Text] [Related]
15. A longitudinally extensive H3 K27M-mutant diffuse midline glioma in an elderly patient clinically mimicking central nervous system inflammation: a case report.
Babarczy K; Reisz Z; Szabo E; Rajda C; Vecsei L; Bodi I; Klivenyi P; Hortobagyi T; Szalardy L
Folia Neuropathol; 2020; 58(4):377-385. PubMed ID: 33480242
[TBL] [Abstract][Full Text] [Related]
16. ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma.
Jackson ER; Duchatel RJ; Staudt DE; Persson ML; Mannan A; Yadavilli S; Parackal S; Game S; Chong WC; Jayasekara WSN; Grand ML; Kearney PS; Douglas AM; Findlay IJ; Germon ZP; McEwen HP; Beitaki TS; Patabendige A; Skerrett-Byrne DA; Nixon B; Smith ND; Day B; Manoharan N; Nagabushan S; Hansford JR; Govender D; McCowage GB; Firestein R; Howlett M; Endersby R; Gottardo NG; Alvaro F; Waszak SM; Larsen MR; Colino-Sanguino Y; Valdes-Mora F; Rakotomalala A; Meignan S; Pasquier E; André N; Hulleman E; Eisenstat DD; Vitanza NA; Nazarian J; Koschmann C; Mueller S; Cain JE; Dun MD
Cancer Res; 2023 May; ():OF1-OF17. PubMed ID: 37195023
[TBL] [Abstract][Full Text] [Related]
17. Potent preclinical sensitivity to imipridone-based combination therapies in oncohistone H3K27M-mutant diffuse intrinsic pontine glioma is associated with induction of the integrated stress response, TRAIL death receptor DR5, reduced ClpX and apoptosis.
Borsuk R; Zhou L; Chang WI; Zhang Y; Sharma A; Prabhu VV; Tapinos N; Lulla RR; El-Deiry WS
Am J Cancer Res; 2021; 11(9):4607-4623. PubMed ID: 34659909
[TBL] [Abstract][Full Text] [Related]
18. Incidence and clinicopathologic features of H3 K27M mutations in adults with radiographically-determined midline gliomas.
Schreck KC; Ranjan S; Skorupan N; Bettegowda C; Eberhart CG; Ames HM; Holdhoff M
J Neurooncol; 2019 May; 143(1):87-93. PubMed ID: 30864101
[TBL] [Abstract][Full Text] [Related]
19. Spinal Cord Diffuse Midline Glioma With Histone H3 K27M Mutation in a Pediatric Patient.
Cheng R; Li DP; Zhang N; Zhang JY; Zhang D; Liu TT; Yang J; Ge M
Front Surg; 2021; 8():616334. PubMed ID: 34222313
[No Abstract] [Full Text] [Related]
20. Detection of histone H3 K27M mutation and post-translational modifications in pediatric diffuse midline glioma via tissue immunohistochemistry informs diagnosis and clinical outcomes.
Huang T; Garcia R; Qi J; Lulla R; Horbinski C; Behdad A; Wadhwani N; Shilatifard A; James C; Saratsis AM
Oncotarget; 2018 Dec; 9(98):37112-37124. PubMed ID: 30647848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
